Clearmind Medicine Inc. has announced the expansion of its Phase I/IIa clinical trial for CMND-100, a proprietary MEAI-based oral treatment candidate for Alcohol Use Disorder (AUD). The expansion includes the activation of an additional clinical site at Johns Hopkins University School of Medicine and the enrollment of the first participant at this location. This follows the earlier enrollment of a participant at Yale School of Medicine. The trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, along with preliminary efficacy indicators such as reductions in alcohol cravings and consumption. Results from this trial have not yet been presented. The trial is a multinational, multicenter study designed to establish the safety and optimal dosing of CMND-100, with the potential to further develop this treatment for AUD.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.